Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

BACKGROUND: Mean survival in cancer trials can be estimated with statistical techniques to extrapolate study survival curves. This methodology was applied to data from the VELOUR trial, where use of the novel biologic aflibercept (ziv-aflibercept in the United States) in combination with fluorouraci...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Joulain, F, Proskorovsky, I, Allegra, C, Tabernero, J, Hoyle, M, Iqbal, S U, Van Cutsem, E
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2013
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3790175/
https://ncbi.nlm.nih.gov/pubmed/24045663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.523
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items